Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders—A Double-blind Randomized Placebo-controlled Trial
Schizophrenia Bulletin · 10.04.2026 · 52 (3)
DOI: 10.1093/schbul/sbag050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 09.05.2026. Verfasst von Sin-Ying Wong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, c/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, …. Hauptthemen laut MEDLINE: Schizophrenia, Benzhydryl Compounds, Glucosides, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation and Technology Fund, The Innovation and Technology Commission, Government of Hong Kong Special Administrative Region.
Abstract (Originalsprache)
Background and Hypothesis Patients with schizophrenia spectrum disorders have elevated cardiovascular risk with obesity and deranged metabolic profiles associated with antipsychotic usage, bearing significant tolls on chronic morbidity and mortality. The present study aims to evaluate the efficacy and tolerability of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in improving weight control and metabolic profile in atypical antipsychotics-treated patients with schizophrenia spectrum disorders. Study Design This double-blind, randomized, placebo-controlled trial studied overweight or obese adults with schizophrenia spectrum disorders (non-diabetic or pre-diabetic) who were taking atypical antipsychotics. Participants recruited from a specialist clinic of a regional public service were randomized to receive empagliflozin or placebo for 16 weeks, in combination with standardized lifestyle intervention through psychoeducation. The primary outcomes were changes in body weight and body mass index (BMI). Changes in other metabolic parameters were examined as secondary outcomes. Linear mixed models were used to study the differences in outcomes between the active and placebo arms.
Results
Of the 52 patients undergoing randomization, the SGLT2i group had significant reductions in body weight (−1.53 kg; 95% CI, −2.60 to −0.47), BMI (−0.53 kg/m2; 95% CI, −0.91 to −0.15), fasting glucose (−0.40 mmol/L; 95% CI, −0.65 to −0.15), and glycated hemoglobin A1c (−0.11%; 95% CI, −0.21 to −0.02) compared with the placebo group (P-values <.05). Adverse events and dropout rates were similar between the 2 groups.
Conclusions
The combined approach of empagliflozin and lifestyle intervention improved weight control and glucose metabolism among patients with schizophrenia spectrum disorders receiving atypical antipsychotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, c/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR, China.
- Department of Psychiatry, Tai Po Hospital/Alice Ho Miu Ling Nethersole Hospital/North District Hospital, New Territories East Cluster, Hospital Authority, Hong Kong SAR, China.
- Department of Psychiatry, Shatin Hospital/Prince of Wales Hospital, New Territories East Cluster, Hospital Authority, Hong Kong SAR, China.
- Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.
- Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China.
ORCID-Profile: Joshua Tsoh
Förderung
- Innovation and Technology Fund
- The Innovation and Technology Commission
- Government of Hong Kong Special Administrative Region
Zitieren
APA
Wong, S. Y., Chan, S. C., Mo, Y. F., Tsoh, J., Wong, W. O., Yu, T. M., Chan, S. S., & Lai, H. M. (2026). Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders—A Double-blind Randomized Placebo-controlled Trial. Schizophrenia Bulletin, 52(3). https://doi.org/10.1093/schbul/sbag050
Vancouver
Wong SY, Chan SC, Mo YF, Tsoh J, Wong WO, Yu TM, et al. Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders—A Double-blind Randomized Placebo-controlled Trial. Schizophrenia Bulletin. 2026;52(3). doi:10.1093/schbul/sbag050
BibTeX
@article{Wong2026,
author = {Wong, Sin-Ying and Chan, Sheung-Chun and Mo, Yi-Man Flora and Tsoh, Joshua and Wong, Wing-Ho Oscar and Yu, Tsun-Ming and Chan, Sau-Man Sandra and Lai, Hei-Ming},
title = {Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders—A Double-blind Randomized Placebo-controlled Trial},
journal = {Schizophrenia Bulletin},
year = {2026},
volume = {52},
number = {3},
doi = {10.1093/schbul/sbag050}
}
EUVIMED